aiming to improve the standard-of-care for cancer patients,” said Professor Ugur Sahin, BioNTech’s chief executive and co-founder.

We look forward to providing more updates this year across our oncology portfolio, including our bispecific antibody and ADC programs,” said Ugur Sahin, CEO and Co-Founder of BioNTech.

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 ...

BioNTech CEO and co-founder Professor Ugur Sahin said: "We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional check ...

BioNTech co-founder Ugur Sahin said the company believes the active ingredient has the potential to set a new standard of treatment in certain cancers. Several studies with the active ingredient ...

EU residents will have access to Omicron-adapted vaccines before the start of the winter season," said Prof Ugur Sahin, BioNTech's chief executive. The companies said they are also planning to ...

Buldukları aşı ile BioNTech hisseleri büyük değer kazanırken, şimdi 100 Euro’lara kadar indi. Şirketin son 4 haftadaki kaybı yüzde 12 oldu. Bunun nedenlerinden biri olarak Amerikan ...

Today, I'm joined by the following members of BioNTech's management team: Ugur Sahin, Chief Executive Officer and Co-Founder; Ozlem Tureci, Chief Medical Officer and Co-Founder; Jens Holstein ...

Today, I'm joined by the following members of BioNTech's management team: Ugur Sahin, Chief Executive Officer and Co-Founder; Ozlem Tureci, Chief Medical Officer and Co-Founder; Jens Holstein ...